Nano-X Imaging Croissance future
Future contrôle des critères 2/6
Nano-X Imaging devrait augmenter ses bénéfices et ses revenus de 67.1% et de 43.7% par an respectivement, tandis que le BPA devrait croître de croître de 70.9% par an.
Informations clés
67.1%
Taux de croissance des bénéfices
70.90%
Taux de croissance du BPA
| Healthcare croissance des bénéfices | 19.6% |
| Taux de croissance des recettes | 43.7% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 25 Jun 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • Jun 26
Nano-X Withdraws Guidance, Signals Rocky Road Ahead
Summary Nano-X Imaging Ltd. is downgraded to a sell as its narrative shifts from disruptive growth to execution and survival. NNOX's Q1 revenue rose 53% to $4.3M, but core Nanox.ARC hardware contributed minimally; most revenue stems from teleradiology and AI/Health IT. Withdrawn FY26 guidance, persistent cash burn, and explicit going concern warnings highlight severe liquidity and execution risks. Despite early commercial traction and partnerships, delayed deployments and a shrinking cash runway make near-term dilution highly likely. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 17
NNOX: New Distribution Agreements Will Support Future Stock Upside Potential
Analysts have reduced their Nano-X Imaging price target by $2 to reflect updated assumptions around long term revenue growth, profit margins, and future P/E multiples. What’s in the News for Nano-X Imaging Nano-X Imaging signed a U.S. distribution agreement through its subsidiary Nanox Impact Inc.Mise à jour du récit • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.
Mise à jour du récit • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.Mise à jour du récit • Apr 12
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).Mise à jour du récit • Mar 28
NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.Mise à jour du récit • Mar 12
NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.Mise à jour du récit • Feb 25
NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).Mise à jour du récit • Feb 10
NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.Mise à jour du récit • Jan 27
NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).Mise à jour du récit • Jan 12
NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.Mise à jour du récit • Dec 26
NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.Mise à jour du récit • Dec 12
NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).Article d’analyse • Oct 31
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Mise à jour du récit • Aug 15
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.Article d’analyse • May 27
Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
One thing we could say about the analysts on Nano-X Imaging Ltd. ( NASDAQ:NNOX ) - they aren't optimistic, having just...
Nouveau récit • Apr 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.Article d’analyse • Apr 01
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 14
Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Summary Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system. Expect Nano-X to reach inflection point for revenue growth due to FDA approvals and the huge need for cost-effective X-ray monitoring and analyzing solutions. Read the full article on Seeking AlphaSeeking Alpha • Jan 04
Nano-X Imaging's Recent Surge Is Undeserved
Summary Nano-X Imaging shares surged 50.8% in a month, but I maintain a "sell' rating due to overvaluation and poor fundamentals. Despite some positive developments, Nano-X generates minimal revenue, significant net losses, and cash outflows, necessitating future capital raises. Recent FDA clearances and accolades are promising, but there's no concrete evidence that their technologies will achieve commercial success. The company's declining net cash balance and unjustified valuation reinforce my bearish stance on Nano-X Imaging. Read the full article on Seeking AlphaArticle d’analyse • Dec 05
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Key Insights Nano-X Imaging to hold its Annual General Meeting on 10th of December Total pay for CEO Erez Meltzer...Article d’analyse • Nov 25
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Sep 29
Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Summary Nano-X Imaging has seen a significant decline in stock value, shedding over 37% since February, with no strong catalysts to reverse the trend. Nvidia’s small stake in Nano-X briefly boosted the stock, but without further investment or partnership, investor excitement has waned. Persistent financial losses, slow revenue growth, and limited global reach make Nano-X a high-risk investment with potential for further value erosion. Read the full article on Seeking AlphaArticle d’analyse • Apr 05
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 01
Nano-X Imaging: System Deployments Finally Begin
Summary Nano-X Imaging is executing its long-awaited roll-out strategy with multiple Nanox.ARC system deployments in the U.S. The company has also made progress in Africa and Latin America with installations and distribution agreements. However, financial performance is still lagging with scant details on how Nano-X will scale up to commercial scale. The story is improving, but there are still too many concerns for me to invest in NNOX stock. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 109 | -11 | N/A | N/A | 2 |
| 12/31/2027 | 55 | -28 | N/A | N/A | 3 |
| 12/31/2026 | 29 | -37 | N/A | -31 | 3 |
| 3/31/2026 | 15 | -76 | -50 | -44 | N/A |
| 12/31/2025 | 13 | -75 | -45 | -41 | N/A |
| 9/30/2025 | 12 | -56 | -45 | -41 | N/A |
| 6/30/2025 | 12 | -56 | -42 | -38 | N/A |
| 3/31/2025 | 12 | -55 | -41 | -37 | N/A |
| 12/31/2024 | 11 | -54 | -39 | -37 | N/A |
| 9/30/2024 | 11 | -50 | -41 | -39 | N/A |
| 6/30/2024 | 10 | -57 | -44 | -42 | N/A |
| 3/31/2024 | 10 | -61 | -45 | -44 | N/A |
| 12/31/2023 | 10 | -61 | -48 | -45 | N/A |
| 9/30/2023 | 10 | -103 | -49 | -47 | N/A |
| 6/30/2023 | 10 | -101 | -45 | -42 | N/A |
| 3/31/2023 | 9 | -103 | -48 | -43 | N/A |
| 12/31/2022 | 9 | -113 | -51 | -43 | N/A |
| 9/30/2022 | 8 | -82 | -63 | -50 | N/A |
| 6/30/2022 | 5 | -77 | -65 | -49 | N/A |
| 3/31/2022 | 3 | -71 | -66 | -45 | N/A |
| 12/31/2021 | 1 | -62 | -61 | -38 | N/A |
| 9/30/2021 | N/A | -59 | N/A | N/A | N/A |
| 6/30/2021 | N/A | -56 | N/A | N/A | N/A |
| 3/31/2021 | N/A | -49 | N/A | N/A | N/A |
| 12/31/2020 | N/A | -44 | -36 | -22 | N/A |
| 9/30/2020 | N/A | -44 | -13 | -12 | N/A |
| 6/30/2020 | N/A | -35 | -9 | -9 | N/A |
| 3/31/2020 | N/A | -29 | N/A | N/A | N/A |
| 12/31/2019 | N/A | -23 | N/A | -6 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: NNOX devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: NNOX devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: NNOX devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de NNOX ( 43.7% par an) devrait croître plus rapidement que le marché US ( 12.6% par an).
Croissance élevée des revenus: Le chiffre d'affaires de NNOX ( 43.7% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de NNOX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/29 09:06 |
| Cours de l'action en fin de journée | 2026/06/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Nano-X Imaging Ltd. est couverte par 9 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Scott Henry | Alliance Global Partners |
| Ravi Misra | Berenberg |